YDES Stock Price, Chart, Stats & News
YD Bio Limited Ordinary Shares (YDES) does not currently pay a dividend.
YDES chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.40% |
ROA | -100.79% |
ROE | 46.53% |
D/E | – |
Interest coverage ratio | – |
YDES valuation
P/E | – |
P/S | – |
P/B | -1.66x |
P/CF | -22.65x |
P/FCF | -468.42x |
P/OCF | -22.65x |
PEG | 0.07x |
EV multiple | -184.41x |
About
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma. It also provides Hydrogel (Hioxifilcon A) Soft (Hydrophilic) Contact Lens, a spherical and aspherical lenses.
Similar securities
Based on sector and market capitalization
